Early Development Leader

Early Development Leader

The Early Development Leader (EDL) is a high-responsibility, strategic role, critical for developing the vision and trajectory for a medicine that maximizes its opportunity for GSK and benefit for patients.

The EDL is the single point of accountability to lead the development of a medicine from initiation of Lead Optimization through Proof of Concept (PoC), defining the criteria necessary to identify and progress game-changing medicines through creative and innovative experimental design.

By working with various stakeholders across R&D, the EDL obtains and manages associated resources and delivers evidence in line with the strategic vision and organizational strategy to support progression beyond PoC for a clearly differentiated medicine.

Key Responsibilities

Leadership of the Early Development Strategy :

• Contributes to and establishes the development strategy to support the Medicine Profile (MP)
• Secures input and alignment from late-stage Development, Commercial and Medical
• Ensures asset development strategy is kept current, as internal priorities shift and the external landscape changes

Matrix Leadership of the Early Development Team (EDT) :

Business Partnering beyond the EDT :

Basic Qualifications

We are looking for professionals with these required skills to achieve our goals :

Preferred Qualifications

If you have the following characteristics, it would be a plus :

Why GSK?

Our values and expectations are at the heart of everything we do and form an important part of our culture. These include Patient focus, Transparency, Respect, Integrity along with Courage, Accountability, Development, and Teamwork. As GSK focuses on our values and expectations and a culture of innovation, performance, and trust.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive. We get ahead of disease by preventing and treating it with innovation in specialty medicines and vaccines. We focus on four therapeutic areas : respiratory, immunology and inflammation; oncology; HIV; and infectious diseases to impact health at scale.

People and patients around the world count on the medicines and vaccines we make, so we're committed to creating an environment where our people can thrive and focus on what matters most. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we deliver for patients, shareholders and our people.